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Abstract
Background: The efficacy of a single 2.5 mg/kg dose of afoxolaner (NexGard®, Merial) against induced Otodectes
cynotis infestations was assessed in eight afoxolaner-treated dogs, compared to eight untreated dogs.
Methods: After O. cynotis infestations were established and confirmed by otoscopic assessments in 16 dogs, all of
the dogs were included in the study and allocated to two separate treatment groups. The first group of eight ear
mite-infested dogs remained untreated, while afoxolaner was administered orally to the second group of dogs at
the minimum recommended dose once on Day 0. Otoscopic assessments performed on all dogs (Days -7, -2, 14
and 28) confirmed the presence or absence of live mites throughout the study. No serious adverse events were
recorded throughout the study, and no adverse events were likely related to the administration of NexGard.
Results: By Day 28, seven out of eight untreated dogs were still infested with ear mites, while only two out of
eight afoxolaner-treated dogs were infested, with one and four ear mites, respectively. On Day 28, the reductions of
mite counts in the afoxolaner-treated group versus those of the control dogs were 98.5% based on geometric
means, and 99.4% based on arithmetic means. Significantly fewer (P < 0.05) live mites were present in the
afoxolaner-treated group than the untreated group on Day 28.
Conclusion: The results of this study demonstrated that a single oral administration of afoxolaner at the minimum
recommended dose is highly effective (>98%) in treating dogs with induced O. cynotis infestations.
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Background
The ear mite Otodectes cynotis, the causative organism
of otodectic mange [1], is a very common non-
burrowing, surface-living [2] acarian which infests cats,
dogs and many other carnivores. Otodectes cynotis is
found all over the world and primarily infests the ear ca-
nals of its host; however, it has also been found on head,
back and tail in heavy infestations [1, 2]. The irritation
caused by the mites often results in the host scratching
its ears and shaking its head, which can lead to lacera-
tions associated with the affected ear(s) or the formation
of an auricular hematoma. Secondary yeast and bacterial
infections often occur in the presence of heavy ear mite
infestations.
Transmission of ear mites occurs by direct contact
with an infested host [1–3], most commonly with the
transmission of the mites from mother to kittens or
puppies before weaning. Clinical signs which can lead to
the suspicion of otodectic mange include bilaterally
pruritic otitis with dry, blackish-brown cerumen in the
host’s ear canal; self-induced ear lesions; aural hemato-
mas; and pruritic lesions on the face and neck. Diagnosis
is usually made through otoscopic examination of the
ear and microscopic examination of cerumen, which
usually contains ear mites of all life stages (eggs, larvae,
nymphs and adults). Additionally, skin scrapings can oc-
casionally reveal ear mites [3]. It is important to note
that, if at least one pet in the household is infested with
ear mites, all pets in the household need to be treated
for ear mites, as the mites are highly contagious [1, 4].
Since O. cynotis is a very common parasite of dogs and
cats, it is essential to find effective treatments for
infested pets. Historically, treatment necessitated ear
flushing and cleansing with a mild ceruminolytic agent.
Typical treatments include mineral oil or acaricides
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(monosulfiram, permethrin, or amitraz [3, 4]) directly
administered into the ear canal.
Sometimes treating the ears alone would not solve the
issue. Often to achieve control one would also treat the
whole body with an acaricide dip or topical treatment,
as mites can infest other parts of the body and re-infest
the ears [3]. Later, systemic-topical treatments such as
selamectin and imidacloprid/moxidectin spot on formu-
lations were found to have good systemic activity against
ear mites in the ear canal and on the body [2, 3, 5, 6].
Recently, a new class of insecticides/acaricides, the iso-
xazolines, has demonstrated excellent efficacy against O.
cynotis and other similar parasites [7]. Afoxolaner is an
isoxazoline administered monthly to protect dogs
against fleas and ticks (NexGard®) [7–9]. It is adminis-
tered at a minimum dose of 2.5 mg/kg, and comparative
studies have shown that monthly administrations of
afoxolaner provide outstanding protection against fleas
and ticks [10, 11]. Afoxolaner has also demonstrated to
be highly efficacious against Sarcoptes scabiei [12] and
Demodex canis [13, 14]. Based on these observations,
the present study was undertaken to assess the efficacy
of a single oral administration of afoxolaner (NexGard)
against O. cynotis infestations in dogs.
Methods
Animals
All dogs were a part of a colony at the study site,
Clinvet, and were returned to the colony holding facility
at the conclusion of the study. All animals were man-
aged similarly and with due regard for their well-being.
Trained personnel under the supervision of a veterinar-
ian were responsible for the health of the dogs. All
personnel involved in health assessments, data collection
and physical examinations were blinded to the treatment
allocation of the dogs. To prevent potential bias or
unmasking, the treatment assessments were conducted
in a non-systematic order. All dogs considered were over
6 months of age (age on day of treatment ranged from
2 years and ten months to 8 years and six months), and
acclimatized to the study facility for at least seven days
prior to being artificially infested with O. cynotis mites.
Experimental infection was performed by harvesting mites
by lavage from donor animals with patent natural infesta-
tions, and transferring approximately 50 to 100 mites,
depending on intensity of infection in donor animals, into
each ear of the recipient animal. From this pool of O.
cynotis infested dogs, 16 dogs that ultimately developed
established infections and also met qualification parame-
ters as verified by a veterinarian via clinical examinations
(Days -7 and -2) were included in the study. The study
dogs weighed between 15.4 and 22.0 kg (as weighed on
Day -1) (Table 1). The dogs were of mixed breed (all
mongrels), and were healthy at the initiation of the study,
except for clinical signs associated with the induced O.
cynotis infestations. Nine males and seven females were
included in the study, and the females were not pregnant
or lactating. Once enrolled, dogs were kept individually in
cages under strict isolation conditions, with no physical
contact between animals possible. None of the dogs
included in the study had been treated with a long-lasting
topical or systemic miticidal/acaricidal/insecticidal
product during the 12 weeks preceding Day 0, nor had
they been treated with any isoxazolines for 6 months prior
to Day 0.
Study design and treatment
This study was a randomized, single center, controlled
efficacy study, following a randomized block design, and
all evaluations of efficacy were performed by personnel
in blinded conditions. Each dog was an experimental
unit. For each dog, a total of > 10 live mites in at least
one ear, as well as the presence of ≥ 1 live mite in the
other ear, was necessary for inclusion in the study. Dogs
were enrolled as they qualified, thus Day 0 was not the
same calendar day for all dogs.
Once qualified, dogs were ranked within sex, in de-
scending order of individual pre-administration (Day -2)
live mite count, and were subsequently blocked into
eight replicates of two dogs each. The dogs were then al-
located to untreated group 1 and treated group 2. Dogs
were weighed on Day -1 to ensure that, as close as pos-
sible and without under-dosing, the labeled minimum
dose of afoxolaner (2.5 mg/kg) was administered using
combinations of intact commercially available product
(Table 2). All dogs were observed hourly for four hours
post-administration, for possible adverse events from
product administration.
Otoscopic assessments were performed on all dogs on
Days -7, -2, 14 and 28 to confirm the initial presence,
and subsequent presence or absence, of live mites.
Table 1 Individual dog information/details, as assessed on Day -1
Group 1 (negative control) Group 2 (afoxolaner-treated)
Animal ID Sex Body weight (kg) Animal ID Sex Body weight (kg)
4D9 16A M 17.8 287 466 F 15.4
4DE 28 F F 18.4 CC3 CEE M 19.8
86C 5B7 M 22.0 CD5 B63 F 18.4
956 36 F F 20.2 DF4 840 M 17.2
B2C 7B5 F 18.6 DF5 29E M 17.0
CC5 7C6 F 16.6 E15 130 M 20.8
DF5 E10 M 20.2 E17 62E M 18.2
DF7 CD8 M 21.4 E19 161 F 19.8
Arithmetic mean body
weight in kg: 19.4
Arithmetic mean body
weight in kg: 18.3
Carithers et al. Parasites & Vectors  (2016) 9:635 Page 2 of 5
Ear flushing and mite counts
On Day 28, a qualitative assessment of the ear canals
was performed prior to the flushing procedure to deter-
mine the presence of viable mites. This was followed by
the quantitative assessment of ear mites by ear duct
flushing, complete mite collection and count. The ear
ducts were filled with an appropriate solution of a 5%
aqueous solution of docusate sodium (3 to 4 ml per ear
canal), then the ears massaged externally until sufficient
melting of the ear duct content was observed. The
melted solution for each ear was collected into a labeled
collection container, followed by a saline flush of the ear
duct into the same container. The contents of the con-
tainer were drained into a 38 μm sieve, which was then
rinsed with clean water immediately, and the contents
for each ear were transferred separately into labeled bot-
tles. This procedure was conducted on each ear until
otoscopic examinations revealed that both ears were
clean. The contents of each ear were collected, exam-
ined, and stored separately in the labeled bottles. All col-
lected material was observed microscopically on the
same day, and all observed live mites (adult and imma-
ture) were counted and recorded for each ear.
Statistical analysis
The primary efficacy criterion was the number of live
mites collected from the NexGard-treated group on Day
28, compared to that of the untreated control group on
the same day. The statistical unit was the individual ani-
mal. The average percent reduction in mite counts for
each group was calculated using geometric means: Effi-
cacy (%) against ear mites = 100 × (GMC – GMT)/GMC,
where GMC is the geometric mean number of live mites
in dogs in the untreated group and GMT is the geomet-
ric mean number of live mites in dogs in the treated
group. The groups were compared using a one-way
ANOVA (Proc GLM procedure in SAS) with an admin-
istration effect after a logarithmic transformation on the
mite (count + 1) data, and by using an ANOVA (Proc
GLM procedure in SAS) with an administration effect
on untransformed mite count data.
Additionally, due to large variability in mite counts in
the negative control group, a non-parametric alternative
test (the Mann-Whitney U-test) was used to assess effi-
cacy by comparing median values. SAS version 9.3 TS
Level 1 M2 [15] was used for all statistical analyses. Stat-
istical significance for geometric mean and arithmetic
mean assessments was declared at a two-sided P-value
of 0.05.
Results
Clinical examinations and health observations
None of the clinical signs (mild pruritus, intermittent
head-shaking) associated with the mite infestations ob-
served during any of the clinical examinations were
deemed as serious or affecting overall health and well-
being. The examining veterinarian carefully examined
and judged all enrolled dogs to be fit to continue in the
study, at each assessment throughout the study. No ser-
ious health issues were recorded during the study, with
only mild signs consistent with O. cynotis infestation ob-
served. No adverse events related to the administration
of afoxolaner were observed.
Antiparasitic efficacy
All of the dogs were positive for the presence of ear mites
prior to Day 0 of the study. For the untreated control dogs
(Group 1), the number of live mites found on each dog on
Day 28 ranged from 0 to 477. For the afoxolaner-treated
dogs (Group 2), one dog harbored one mite, another had
four live mites, with the remaining six dogs having no live
mites found by Day 28. Based on geometric means, an
average of 22.3 live mites per negative control dog, and an
average of 0.3 live mites per afoxolaner-treated dog, was
recorded after ear flushing. Calculating based on arith-
metic means, an average of 109.9 live mites per negative
control dog, and an average of 0.6 live mites per
afoxolaner-treated dog, was recorded after ear flushing.
Based on both geometric (one-way ANOVA with a treat-
ment effect) means (ANOVA: F(1,14) = 11.74, P = 0.0041)
and arithmetic (Mann-Whitney U-test) assessments (W(1)
= 43.5, Z = -2.6354, P = 0.0084) significantly fewer live
mites were present in the afoxolaner-treated group than
were present in the untreated group by Day 28. The per-
cent efficacy of NexGard (afoxolaner) against induced
Otodectes cynotis on Day 28 was calculated to be 98.5%
based on geometric means and 99.4% based on arithmetic
means (Table 3).
Discussion
Otodectes cynotis is a commonly occurring surface-
dwelling mite that can easily transfer between suitable
hosts [1–3]. Since these mites can exist on infected hosts
Table 2 Administration of NexGard (afoxolaner) at ~2.5 mg/kg
to the afoxolaner-treated group (Group 2) on Day 0
Animal ID Body weight
(kg)
Chews administered Actual final
dose (mg/kg)
2003287 466 15.4 1 × 28.3 mg & 1 × 11.3 mg 2.57
CC3 CEE 19.8 1 × 28.3 mg & 2 × 11.3 mg 2.57
CD5 B63 18.4 1 × 28.3 mg & 2 × 11.3 mg 2.77
DF4 840 17.2 4 × 11.3 mg 2.63
DF5 29E 17.0 4 × 11.3 mg 2.66
E15 130 20.8 5 × 11.3 mg 2.72
E17 62E 18.2 1 × 28.3 mg & 2 × 11.3 mg 2.80
E19 161 19.8 1 × 28.3 mg & 2 × 11.3 mg 2.57
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outside the ear canals [1, 2], in order to effectively treat
existing infestations, or potentially prevent infestations,
effective systemic acaricidal products should be utilized.
Properly ascertaining the overall efficacy of antiparasitic
products often requires multiple studies be performed.
Typically, the first such study performed is a controlled
laboratory study utilizing the minimum target dose, real-
izing that studies of different scales will follow, should
the results indicate a potential for success.
This study was designed to assess the efficacy of the
minimum dose of afoxolaner against existing infestations
of O. cynotis in dogs under controlled, laboratory condi-
tions. The present study demonstrates that treatment with
a single oral dose (at or approaching the minimum recom-
mended dosage of 2.5 mg/kg) of afoxolaner (NexGard®
Chewables) resulted in a rapid reduction in ear mite num-
bers, suggesting that a single oral administration of
NexGard is highly effective (> 98%) against O. cynotis in-
festations in dogs, as assessed 28 days post-administration.
This is comparable to efficacy achieved when afoxolaner
was tested against other mite species infesting dogs,
namely Sarcoptes scabiei (100% efficacy based on mite
counts) [12] and Demodex spp., with > 99% efficacy based
on mite counts in a well-controlled study [12] and reso-
lution of cases under field conditions [14].
Conclusion
The high level of efficacy achieved with a single, mini-
mum dose of NexGard® (afoxolaner) in the present study
would seem to justify additional work to gather further
evidence of the treatment and control capabilities of
afoxolaner against O. cynotis, also when considering high
efficacy obtained against other mite species infesting
dogs.
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